Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Apr;42(2):99-105.
doi: 10.1590/S1806-37562015000000063.

Administering the Sarcoidosis Health Questionnaire to sarcoidosis patients in Serbia

[Article in English, Portuguese]
Violeta Mihailović-Vučinić  1 , Branislav Gvozdenović  2 , Mihailo Stjepanović  3 , Mira Vuković  4 , Ljiljana Marković-Denić  3 , Aleksandar Milovanović  5 , Jelica Videnović-Ivanov  3 , Vladimir Žugić  1 , Vesna Škodrić-Trifunović  1 , Snežana Filipović  3 , Maja Omčikus  3
Affiliations

Administering the Sarcoidosis Health Questionnaire to sarcoidosis patients in Serbia

[Article in English, Portuguese]
Violeta Mihailović-Vučinić et al. J Bras Pneumol. 2016 Apr.

Abstract
in English, Portuguese

Objective: The aim of this study was to use a Serbian-language version of the disease-specific, self-report Sarcoidosis Health Questionnaire (SHQ), which was designed and originally validated in the United States, to assess health status in sarcoidosis patients in Serbia, as well as validating the instrument for use in the country.

Methods: This was a cross-sectional study of 346 patients with biopsy-confirmed sarcoidosis. To evaluate the health status of the patients, we used the SHQ, which was translated into Serbian for the purposes of this study. We compared SHQ scores by patient gender and age, as well as by disease duration and treatment. Lower SHQ scores indicate poorer health status.

Results: The SHQ scores demonstrated differences in health status among subgroups of the sarcoidosis patients evaluated. Health status was found to be significantly poorer among female patients and older patients, as well as among those with chronic sarcoidosis or extrapulmonary manifestations of the disease. Monotherapy with methotrexate was found to be associated with better health status than was monotherapy with prednisone or combination therapy with prednisone and methotrexate.

Conclusions: The SHQ is a reliable, disease-specific, self-report instrument. Although originally designed for use in the United States, the SHQ could be a useful tool for the assessment of health status in various non-English-speaking populations of sarcoidosis patients.

Objetivo:: O objetivo deste estudo foi utilizar uma versão no idioma sérvio do Sarcoidosis Health Questionnaire (SHQ), um questionário de autorrelato doença-específico, concebido e originalmente validado nos EUA, para verificar o estado de saúde de pacientes com sarcoidose na Sérvia, além de validar o instrumento para uso no país.

Métodos:: Estudo transversal com 346 pacientes com sarcoidose confirmada por biópsia. Para avaliar o estado de saúde dos pacientes, utilizamos o SHQ, o qual foi traduzido para o sérvio para os propósitos deste estudo. Comparamos os escores do SHQ por gênero, idade, duração da doença e tratamento. Escores do SHQ mais baixos indicam pior estado de saúde.

Resultados:: Os escores do SHQ demonstraram diferenças no estado de saúde entre os subgrupos de pacientes avaliados. O estado de saúde foi significativamente pior entre as mulheres e pacientes mais velhos, assim como entre aqueles com sarcoidose crônica ou com manifestações extrapulmonares da doença. A monoterapia com metotrexato associou-se com melhor estado de saúde do que a monoterapia com prednisona ou a terapia combinada com prednisona e metotrexato.

Conclusões:: O SHQ é um instrumento de autorrelato doença-específico confiável. Embora originalmente concebido para uso nos EUA, o SHQ pode ser uma ferramenta útil na avaliação do estado de saúde de populações de pacientes com sarcoidose em vários países de língua não inglesa.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Statement on sarcoidosis Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999;160(2):736–755. - PubMed
    1. Wirnsberger RM, de Vries J, Breteler MH, van Heck GL, Wouters EF, Drent M. Evaluation of quality of life in sarcoidosis patients. Respir Med. 1998;92(5):750–756. doi: 10.1016/S0954-6111(98)90007-5. - DOI - PubMed
    1. Chang B, Steimel J, Moller D, Baughman RP, Judson MA, Yeager H., Jr Depression in Sarcoidosis. Am J Respir Crit Care Med. 2001;163(2):329–334. doi: 10.1164/ajrccm.163.2.2004177. - DOI - PubMed
    1. Judson MA. Sarcoidosis: clinical presentation, diagnosis, and approach to treatment. Am J Med Sci. 2008;335(1):26–33. doi: 10.1097/MAJ.0b013e31815d8276. - DOI - PubMed
    1. Judson MA. An approach to the treatment of pulmonary sarcoidosis with corticosteroids: the six phases of treatment. Chest. 1999;115(4):1158–1165. doi: 10.1378/chest.115.4.1158. - DOI - PubMed

Publication types